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Abstract 
Drug-resistant tuberculosis poses a serious challenge to global control of TB. These forms of TB do not 
respond to the standard six-month treatment; it can take two years or more to treat with category IV 
drugs that are less potent, more toxic and much more expensive. Treatment of multi-drug resistant 
tuberculosis is still evolving in Nigeria. This case report highlights the side effects of cycloserine used to 
treat a multi-drug resistant tuberculosis patient in Calabar. Five days into therapy, he became 
disoriented, abusive and physically aggressive. He also displayed negativisim with paranoid delusions 
and insomnia. He was managed by a psychiatrist with anti-psychotic drugs. The dose of cycloserine 
was also reduced while that of pyridoxine was increased. He remained in a state of periodic confusion 
and psychosis for nine days after which his condition ameliorated. It is imperative that clinicians involved 
in treating multi-drug resistant tuberculosis are conversant with the side effects of category IV drugs. 
Acute psychosis from cycloserine toxicity requires prompt intervention by trained medical personnel 
using the relevant psychotropic medications. Reduction in dosage or outright stoppage of cycloserine in 
such situations should be considered. Use of pyridoxine in large doses also appears to be beneficial.  
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This is a case report of a 28 year old male 
pulmonary tuberculosis patient presenting at the 
Lawrence Henshaw Memorial Hospital Calabar, 
Nigeria for care. Drug susceptibility testing done 
on his sputum sample showed resistance to 
isoniazid, rifampicin, ethambutol and 
streptomycin.   
 
He had been previously diagnosed with 
tuberculosis in 2007 for which he received 
treatment for just three months. This three 
months of therapy consisted of 2 months of 
isoniazid, rifampicin, ethambutol and 
pyrazinamide and 1 month of isonizid and 
rifampicin. He then decided to discontinue 
treatment because he felt much better. In 2009, 
he was re-treated for tuberculosis for 6 months 
during which streptomycin injection was 
incorporated. 
 
He was not on any long-term medications and 
had no background mental disorder. 
He was unmarried, did not smoke and did not 
abuse illegal drugs or alcohol. 
 
Examination revealed a young man who was 
pale with no peripheral lymph node enlargement 
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or finger clubbing. His weight was 55 kg, height 
1.65m and Body Mass Index (BMI) 20.2. His vital 
signs were temperature 36.8 oC, respiratory rate 
22/min, pulse 90/min and blood pressure 
120/80mmHg. 
 
Chest examination revealed coarse crackles in 
the left middle and lower lung zones. 
His chest x-ray showed fibrotic strands in the left 
upper lung zone with diffuse pulmonary infiltrates 
in the left middle and lower lung zones. 
 
His haemoglobin estimation was 11.6 g/dl and 
the white cell count with differentials were 
normal. Pure tone audiometry revealed a 
bilateral mild conductive hearing loss. His 
urinalysis, serum electrolytes, liver function, 
thyroid function and fasting blood sugar tests 
were all normal. He also tested negative for 
human immunodeficiency virus. 
 
A diagnosis of multidrug resistant (MDR) 
pulmonary tuberculosis was made and he was 
admitted into the MDR-TB ward of the facility. He 
was commenced on a supervised Category IV 
treatment regimen. The 8-month intensive phase 
of this regimen comprised of daily doses of 
pyrazinamide 1.5 g, kanamycin 1 g, levofloxacin 
750 mg, protionamide 750 mg, cycloserine 
750mg and pyridoxine 150mg.  
 
Three days after commencement of the above 
regimen, he was noticed to be soliloquizing for 
about half an hour at night. When asked about 
this the next morning, he said he had a vivid 
dream in which his deceased grandmother 
appeared and had a conversation with him. He 
appeared otherwise normal and his medications 
were continued.  
 
Five days into therapy, he became disoriented, 
abusive and physically aggressive. He also 
displayed negativism with paranoid delusions 
and insomnia. A diagnosis of acute psychosis 
(probably from cycloserine use) was entertained. 
However, his serum level of cycloserine could 
not be assessed due to lack of facilities. He had 
to be physically restrained and received a dose 
of intravenous diazepam. He was then started on 
a psychiatric regimen of chlorpromazine, 
haloperidol and artane. This sedated him 
somewhat but he continued to be abusive to the 
staff and requested to be discharged. His 
appetite became very poor. He developed 
torticollis 24 h later and the dose of artane was 
increased.  On the 7th day of therapy, he tried to 
escape from the facility by scaling the perimeter 
fence. He was discovered in the process and 
restrained. His anti-tuberculosis medications 
were then reviewed. The dose of cycloserine was 
reduced from 750 mg once daily to 500 mg daily. 
This dose of 500 mg was then delivered as 
250mg twice daily instead of a single daily dose. 
The dose of pyridoxine was also increased to 
200 mg daily. He was also put under close 
observation. A re-check of his liver function and 
electrolytes was done to exclude liver or renal 
damage.  
 
He remained in this state of periodic confusion 
and psychosis for 9 days after which his 
condition ameliorated. He gradually became less 
confrontational and more oriented till he regained 
his pre-treatment mental state. Olanzapine was 
introduced and chlorpromazine was tailed off. He 
continued on his second line anti-tuberculosis 




Drug resistant TB poses a serious challenge to 
global control of TB [1]. Resistance to one anti-
TB drugs is known as mono-resistance. 
Multidrug resistant TB (MDR-TB) is resistance to 
at least isoniazid and rifampicin, the two key first 
line anti-TB drugs in short course chemotherapy 
[1]. These forms of TB do not respond to the 
standard six-month treatment with anti-TB drugs 
and can take two years or more to treat with 
drugs that are less potent, more toxic and much 
more expensive [2].    
 
Nigeria has the tenth largest burden of TB cases 
in the world. The 2011 World Health 
Organization (WHO) report states that Nigeria 
has an estimated MDR-TB rate of 2.2 and 9.4 % 
among new and re-treatment TB cases, 
respectively. Nigeria is therefore ranked 15th 
among the 27 High Burden Countries for MDR-
TB [3]. 
 
To the best of our knowledge, the 
commencement of Category IV treatment for the 
index patient is a landmark achievement in the 
annals of MDR-TB control in Nigeria. This patient 
was the very first to be admitted to the only 
MDR-TB treatment facility in the South-South 
zone of Nigeria which is comprised of six states 
in the federation. Thus, the acute psychosis 
recorded in him was a cause of great concern for 
the national TB control programme. It is 
noteworthy that the Psychiatrist on the Clinical 
Expertise Committee of the MDR-TB facility was 
instrumental to the success recorded in the 
management of this crisis. 
 
The most likely diagnosis to explain this patient’s 
psychosis was cycloserine toxicity. The recorded 
neuropsychiatric side effects of cycloserine 
include psychosis, depression, aggression, 
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paranoia, anxiety, confusion and suicidal ideation 
[4]. Cycloserine has a narrow therapeutic window 
and neurotoxicity from its use is common as it 
readily crosses the blood brain barrier and 
decreases gamma amino butyric acid (GABA) 
production [5]. Ideally, patients receiving more 
than 500 mg daily and those with renal 
dysfunction or suspected toxicity should have 
their Cycloserine plasma concentrations 
monitored and kept below 30 mg/ml. Concurrent 
use of alcohol with cycloserine increases the risk 
of developing psychosis and seizures [4].  
Severe Cycloserine neurotoxicity can be 
managed by suspending the drug for a while. It 
can then be re-introduced at low dosages once 
the patient is back to normal. Due to the long half 
life of cycloserine, patients with side effects may 
take days or weeks to return to normal. For the 
patients who cannot tolerate the re-introduction 
of cycloserine, an alternative drug can be utilized 
[5]. 
 
For less severe manifestations of cycloserine 
toxicity, the dosage of cycloserine can be 
reduced. Antipsychotics are very useful for 
managing neuropsychiatric effects and can be 





As the treatment of MDR-TB fully comes on 
stream in Nigeria, it is imperative that clinicians 
are conversant with the full spectrum of untoward 
side effects that patients on category IV drugs 
could manifest with. Acute psychosis occurring in 
this setting from cycloserine toxicity requires 
prompt intervention by trained medical personnel 
using relevant psychotropic medications. It is 
also expedient to have a psychiatrist on the 
multidisciplinary team to oversee the 
management of such neuropsychiatric 
manifestations. Reduction in dosage or outright 
stoppage of cycloserine in such situations should 
be considered. Use of pyridoxine in large doses 
also appears to be beneficial. In settings where 
the monitoring of drug serum levels is not 
possible, Cycloserine toxicity may be prevented 
by giving the lowest possible dose under close 
hospital supervision. 
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